Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2189102 · 2 trials · 2 indications
Change in HbA1c from baseline following 12 weeks of therapy (that is, HbA1c at week 12 minus HbA1c at baseline). The Least Squares (LS) Mean Value was based on an analysis of covariance (ANCOVA) model with treatment and site as class variables and baseline HbA1c as a continuous covariate.
Clinically significant events were defined as serious AEs (SAEs) and other non-serious AEs regardless of causality. A summary of s SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| 0.6 milligrams (mg) LY2189102 | EXPERIMENTAL | - |
| 18 mg LY2189102 | EXPERIMENTAL | - |
| 180 mg LY2189102 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | 0.9% Sodium Chloride |
| Part A LY2189102 0.1 mg/kg/wk | EXPERIMENTAL | Part A: 2 times (x) 0.1 milligrams/kilogram/week (mg/kg/wk) Loading dose, then 0.1 mg/kg/wk) X 4 weeks (wks), intravenous (IV) Part B: 2 x 0.02 mg/kg/wk Loading dose, then 0.02 mg/kg/wk X 4 wks, IV |
| Part A LY2189102 0.3 mg/kg/wk | EXPERIMENTAL | Part A: 2 x 0.3 mg/kg/wk Loading dose, then 0.3 mg/kg/wk X 4 wks, IV Part B: 2 x 0.15 mg/kg/wk Loading dose, then 0.15 mg/kg/wk X 4 wks, IV |
| Part A LY2189102 1.0 mg/kg/wk | EXPERIMENTAL | Part A: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV Part B: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV |
| Part A LY2189102 2.5 mg/kg/wk | EXPERIMENTAL | Part A: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV Part B: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV |
| Name | Type | Description |
|---|---|---|
| LY2189102 | DRUG | Participants received 2 subcutaneous (SC) injections weekly for 12 weeks. |
| Placebo | DRUG | Participants received 2 SC injections weekly for 12 weeks. |
Inclusion Criteria: * Have Type 2 Diabetes and confirmed by fasting C-peptide levels greater than or equal to 0.8 nanograms per milliliter \[ng/ml\]), with duration of more than 3 months. * Body mass index between 25 and 40 kilograms per square meter (kg/m2). * Stable on diet and exercise alone, wi...
Top 20 of 31 competitors
LY2189102 is an investigational small molecule being studied for Type 2 Diabetes and Rheumatoid Arthritis. It is being developed by Eli Lilly and Company. The drug is in clinical development, with completed trials in both indications, but it is not approved and remains investigational.
LY2189102 is a small molecule developed by Eli Lilly and Company. Its molecular target has not been specified in available data. The drug is being studied for Type 2 Diabetes and Rheumatoid Arthritis, but its mechanism of action is not disclosed.
LY2189102 is developed by Eli Lilly and Company, traded on the NYSE under the ticker LLY. The company is conducting clinical trials for this investigational small molecule in Type 2 Diabetes and Rheumatoid Arthritis.
LY2189102 is in clinical development. A Phase 1 trial for Rheumatoid Arthritis and a Phase 2 trial for Type 2 Diabetes have both been completed. The drug is investigational and not approved for any use.
LY2189102 has two completed trials. NCT00380744 was a Phase 1 safety and pharmacokinetics study in Rheumatoid Arthritis with 121 participants. NCT00942188 was a Phase 2 study in Type 2 Diabetes with 106 participants. Both trials are completed.
LY2189102 is the only name provided for this investigational drug. No alternative names have been reported. It is being studied by Eli Lilly and Company for Type 2 Diabetes and Rheumatoid Arthritis.